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Abstract
Functional endothelial-like cells (EC) have been successfully derived from different cell sources and potentially used for
treatment of cardiovascular diseases; however, their relative therapeutic efficacy remains unclear. We differentiated
functional EC from human bone marrow mononuclear cells (BM-EC), human embryonic stem cells (hESC-EC) and human
induced pluripotent stem cells (hiPSC-EC), and compared their in-vitro tube formation, migration and cytokine expression
profiles, and in-vivo capacity to attenuate hind-limb ischemia in mice. Successful differentiation of BM-EC was only achieved
in 1/6 patient with severe coronary artery disease. Nevertheless, BM-EC, hESC-EC and hiPSC-EC exhibited typical
cobblestone morphology, had the ability of uptaking DiI-labeled acetylated low-density-lipoprotein, and binding of Ulex
europaeus lectin. In-vitro functional assay demonstrated that hiPSC-EC and hESC-EC had similar capacity for tube formation
and migration as human umbilical cord endothelial cells (HUVEC) and BM-EC (P.0.05). While increased expression of major
angiogenic factors including epidermal growth factor, hepatocyte growth factor, vascular endothelial growth factor,
placental growth factor and stromal derived factor-1 were observed in all EC cultures during hypoxia compared with
normoxia (P,0.05), the magnitudes of cytokine up-regulation upon hypoxic were more dramatic in hiPSC-EC and hESC-EC
(P,0.05). Compared with medium, transplanting BM-EC (n = 6), HUVEC (n = 6), hESC-EC (n = 8) or hiPSC-EC (n = 8)
significantly attenuated severe hind-limb ischemia in mice via enhancement of neovascularization. In conclusion, functional
EC can be generated from hECS and hiPSC with similar therapeutic efficacy for attenuation of severe hind-limb ischemia.
Differentiation of functional BM-EC was more difficult to achieve in patients with cardiovascular diseases, and hESC-EC or
iPSC-EC are readily available as ‘‘off-the-shelf’’ format for the treatment of tissue ischemia.
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Introduction
In experimental studies [1] and clinical trials [2–4], human
bone marrow (BM) derived stem cells have been used as potential
cell therapy to enhance angiogenesis in ischemic tissue, however,
their therapeutic application are limited by the ability to obtain
sufficient number of stem cells for transplantation. Furthermore,
aging and underlying cardiovascular risk factors [5], such as
diabetes and heart failure [6] in patients with cardiovascular
diseases affect the number and capacity of their circulating BM-
derived progenitor cells [7,8] which further hamper the effective-
ness of autologous BM cell therapy.
Prior studies [9] have demonstrated that functional endothe-
lial-like cells (EC) can be derived from pluripotent human
embryonic stem cells (hESC) for therapeutic angiogenesis.
Nonetheless, the clinical application of hESC-EC is limited by
the ethical issue related to the generation of hESC as well as
the potential risk of immune rejection. Recent advances in the
generation of human induced pluripotent stem cells (hiPSC)
[10,11,12] may represent an alternative source to derive
functional EC for treatment of cardiovascular diseases. As
hiPSC can be generated in a patient-specific manner, which is
genetically identical to individual patients, they can avoid the
potential immune rejections after transplantation as well as the
ethical concerns on generating hESC [11]. Indeed, functional
EC have been successfully derived from hiPSC [13]. However,
the therapeutic efficacy of hiPSC derived EC for angiogenesis as
compared with hESC-EC or BM stem cells derived EC have
not been studied. Here, we compared the in-vitro and in-vivo
angiogenic effects of EC derived from hiPSC, hESC and human
BM mononuclear cells.
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Methods
Ethics Statement
The patient study was approved by the Institutional Review
Board of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster (HKCTR-725, http://www.hkclinicaltrials.
com), and all subjects provided written informed consent. The
animal study protocol conforms to the Guide for the Care and Use
of Laboratory Animals published by the United States National
Institutes of Health and was approved by the ethics committee of
the University of Hong Kong (1896–09).
Maintenance and Differentiation of Functional
Endothelial-like Cells
Undifferentiated hiPSC: IMR90-iPSC (hiPSC-1, passage 15–
25) and KS1-iPS (hiPSC-2, passage 15–25) [14] and hESC line:
H1 (passage 40–50, WiCell Research Institute, Madison, WI) were
maintained on MatrigelTM (BD Biosciences, MA)-coated dishes
with mTeSR-1TM medium (Stem Cell Technologies, BC,
Canada). Differentiation of EC from hiPSCs and hESCs were
induced using formation of embryoid bodies (EB). Briefly, cell
clusters were digested by 1 mg/ml dispase (Gibco, Gaithersburg,
MD) and re-suspended in differentiation medium which consists of
knockout-DMEM with 20% fetal calf serum (Hyclone, Logan,
UT), 2 mM L-glutamine, 0.1 mM non-essential amino acids and
0.1 mM b-mercaptoethanol (Invitrogen, Carlsbad, CA) in non-
coated dishes for 9 days. The resulting EB were plated on gelatin-
coated 10-cm dish for 7 days. Then the central portions of the
attached EBs were manually dissected out for further expansion
using endothelial growth medium-2 (EGM-2, Lonza, Walkersville,
MD) for 14 days. CD45- CD31+ cells were then isolated by MoFlo
XPD cell sorter (Beckman-Coulter, Fullerton, CA) and designated
as hESC-EC and hiPSC-EC. For characterization, 4.8 mg/ml of
DiI labeled acetylated low-density lipoprotein (DiI-AcLDL,
Molecular Probes, Eugene, OR) was added and incubated at
37uC for 5 hour. Cells were washed by phosphate buffered saline,
fixed in 2% paraformaldehyde for 10 minutes and then stained by
10 mg/ml of Ulex europaeus Lectin-FITC (Sigma Aldrich, St. Louis,
MO) for 1 hour at room temperature [9]. CD31, von Willebrand
factor (vWF) and intercellular adhesion molecule-1 (ICAM-1)
immunofluorescence staining was performed by the endothelial
cell characterization kit (Chemicon, Temecula, CA). Fluorescence-
activated cell analysis (FACS) was performed with PE-labeled
antibodies against CD31 (BD Bioscience, San Jose, CA), vWF
(Beckman Coulter, Indianapolis, IN) and Kinase insert domain
receptor (KDR; Sigma, St Louis, MO). Human umbilical cord
endothelial cells (HUVEC) were cultured under standard condi-
tion in EGM-2 growth medium (Lonza, walkerville, MD) as
a stable human endothelial cell control.
Differentiation of EC from Human Bone Marrow Cells
BM-MNCs were obtained from patients recruited into the
placebo arm of our previous clinical trial on the use of direct
endomyocardial transplantation of BM mononuclear cells for
treatment of end-staged ischemic heart diseases [15] (Table 1).
From each patient, 40 ml of BM blood was obtained from right
iliac crest after local anesthesia. In brief, BM mononuclear cells
were isolated by Ficoll (GE Healthcare, Amersham, UK) density
gradient centrifugation, and plated to gelatin-coated plate at
a density of 16106 per ml in 6 wells plate with EGM2 medium.
The viability of the cells at the time of harvest was greater than
95%. Attached cells were harvested at Day 14 with CD31+ sorting
as described above and designated as BM derived endothelial-like
cells (BM-EC).
Angiogenic Tube Formation and Migration Assay
Tube formation of the hiPSC-1-EC, hiPSC-2-EC, hESC-EC,
BM-EC and HUVEC were assessed with the In-Vitro Angiogenesis
Assay Kit (Chemicon, Temecula, CA) with 16104 cells as
described with modifications [9]. Modified Boyden Chamber
assay was preformed with 16104 cells of cells (hiPSC-1-EC,
hiPSC-2-EC, hESC-EC, BM-EC and HUVEC) placed in the
upper chamber of the TranswellH pore Polycarbonate Membrane
Insert (Corning, Lowell, MA) in EBM2 medium with 1% fetal
bovine serum. The chamber was placed in a 24-well plate
containing EGM2 medium with or without 50 ng/ml vascular
endothelial growth factor (VEGF) as chemo-attractant and
incubated at 37uC for 24 hours. Then the lower side of the filter
was washed with phosphate buffered saline and fixed with 2%
paraformaldehyde. Migrated cells were visualized by hematoxylin
staining.
Cytokine Release
Conditioned medium was obtained by cultivating 16105
hiPSC-1-EC, hiPSC-2-EC, hESC-EC, BM-EC and HUVEC with
basal EBM2 medium (without supplement) for 5 days under
normoxic (21% O2, 5% CO2) or hypoxic (0.5% O2, 5% CO2)
condition using the BioSpherix OxyCycler C42 system (Bio-
Spherix, Redfield, NY) and subjected to cytokine analysis:
epidermal growth factor (EGF), basic fibroblast growth factor
(FGF-B), hepatocyte growth factor (HGF), leptin, VEGF, placental
growth factor (PIGF) and stromal derived factor-1 (SDF-1);
adhesion molecules including, ICAM1 and vascular cell adhesion
molecule (VCAM) using Procarta multiplex bead-based immuno-
assay kit (Affymetrix, Fremont, CA) according to manufacturer’s
instructions. Data acquisition and analysis were done using Bio-
Plex Manager software version 4.1.1. Cell numbers were counted
after the 5 days incubation for normalization.
In-vivo Functional Effects of Cell Transplantation into
Animal Model of Critical Hind-Limb Ischemia
Critical hind-limb ischemia was induced in male severe
combined immunodeficient mice after anesthetized with xylazine
(20 mg/kg) and ketamine (100 mg/kg) by intraperitoneal injection
[16]. The femoral artery was excised from its proximal origin as
a branch of the external iliac artery to the distal point where it
bifurcates into the saphenous and popliteal arteries. After arterial
ligation, mice were immediately assigned to the following
experimental groups: hiPSC-1-EC group (n= 8), hiPSC-2-EC
group (n= 8), hESC-EC group (n= 8), BM-EC group (n= 6),
HUVEC group (n = 6) and the medium group (medium, n= 6). In
each animal, a total of 36106 cells (30 ml) or medium (EGM-2)
was injected intramuscularly into 3 sites of the gracilis muscle at
the medial thigh of the ischemic hind-limbs. Serial laser Doppler
imaging analysis (Moor Instruments, Devon, UK) was performed
to monitor the blood flow of hind-limbs immediately, at Day 7, 14,
21 and 28 after femoral artery ligation and cell-transplantation.
The digital color-coded images were analyzed to quantify the
blood flow in the region from the knee to the toe, the mean values
of perfusion were calculated.
At Day 28, tissue from the ischemic limb was harvested and
formalin fixed. Mouse monoclonal anti-vWF (Chemicon, Teme-
cula, CA) was used to determine the capillary density on paraffin
embedded tissues using standard immunostaining procedure.
Arteries were stained with mouse monoclonal anti-a-smooth
muscle actin antibody (Serotech, Raleigh, NC). Retention of
transplanted cells was tracked by anti-human nuclear antigen
antibody (HNA; Chemicon International, Temecula, CA) staining.
Endothelial Cells Derived from Human Stem Cells
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To monitor the cell fate after transplantation of hiPSC-EC and
hESC-EC, luciferase-expressing-hiPSC-1-EC and hESC-EC was
generated, cultured in-vitro and expanded before transplantation.
In brief, luciferase gene were transduced into hiPSC-1-EC and
hESC-EC by lentivirus-mediated transfer and selected in the
present of 1 ug/ml puromycin, respectively. After transplanting
the luciferase-expressing-hiPSC-1-EC (n= 8) and hESC-EC (n= 8)
into the ischemic limb, labeled cells were tracked with the IVIS
200 Bioluminescence Imaging System (Xenogen Biosciences,
Cranbury, NJ) after intraperitoneal injection of 150 mg/kg D-
luciferin (Xenogen Biosciences, Cranbury, NJ) at Day 7, 14 and 28
after cell transplantation. We failed to label BM-EC as they have
limited passaging capacity. Signals were analyzed with the Living
Image Software (Xenogen Biosciences, Cranbury, NJ).
Statistical Analysis
Data are expressed as mean 6 SEM. Statistical comparisons
were performed using Student’s t-test or one-way ANOVA, as
appropriate. The distribution pattern of cytokines levels were
highly skewed, so these variables were log-transformed to
normalize their distribution before analysis. Two-way ANOVA
test was performed to compare different groups with time. Post-
hoc Bonferroni’s correction for multiple comparisons was used. All
p values ,0.05 were considered statistically significant.
Results
EC Differentiation
Differentiation of EC from hiPSC-1, hiPSC-2 and hESC were
performed. After culturing for 3 weeks on EGM-2, EC outgrowth
was observed from all hiPSC-1, hiPSC-2 and hESC (Figure 1A).
BM mononuclear cells were obtained from a group of 6 patients
and cultured in the EGM-2 for 14 days. However, functional EC
could only be derived from 1/6 (17%) patient’s BM mononuclear
cells. Culture of BM mononuclear cells obtained in the other 5
patients failed to yield any CD31+ cells. During the differentiation,
those BM mononuclear cells from these 5 patients failed to
proliferate and the majority of the cells showed nuclear
fragmentation, suggesting cellular apoptosis. This finding high-
lights the difficulty in obtaining functional EC from patient’s
autologous BM cells for transplantation.
Immunofluorescence staining showed that hiPSC-1-EC, hESC-
EC and BM-EC display the characteristic phenotypes of
endothelial cells, including uptake of DiI-Ac-LDL and expression
of lectin as the control HUVEC (Figure 1A). Although double
sorting for CD45 negative and CD31 positive was not performed
in BM-EC due to the limited number of cells yielded, flow
cytometry analysis revealed that only 5% of them were CD45
positive. Indeed, .90% of these differentiated EC were double
positive for CD31 and KDR and .80% of them were CD31,
vWF and KDR positive as determined by flow cytomety. There
were no statistical significant difference in the expression of EC-
surface markers between hiPSC-1-EC, hiPSC-2-EC, hESC-EC
and BM-EC, and resemble to the expression in HUVEC
(Figure 1B, all P.0.05).
Functional Assays of EC
The in-vitro functional capacity of EC was examined by their
ability to form capillary like network on Matrigel in the tube-
formation assay. CD31+ hiPSC-EC, hESC-EC, BM-EC, and
HUVEC were plated onto Matrigel, lumen structure of vascular
network were formed after 6 hours of plating (Figure 2A). There
were no statistical differences in the tube formation ability between
hiPSC-1-EC, hiPSC-2-EC, hESC-EC and BM-EC (Figure 2A, all
P.0.05).
Migration of EC through the endothelial lining is a key step in
angiogenesis and vascular repair. Therefore, the migration ability
of the hiPSC-1-EC, hiPSC-2-EC, hESC-EC and BM-EC was
compared using the modified Boyden chamber assay. As
compared with HUVEC and their corresponding controls with
medium alone, hiPSC-1-EC, hiPSC-2-EC, hESC-EC and BM-EC
showed comparable enhancement in migration ability with VEGF
as the endothelial specific chemo-attractant (P,0.05). However,
there were no significant differences in their migration ability
among the five groups (Figure 2B, all P,0.05).
Paracrine Secretion of Derived EC
The cytokine secretion profiles of EC derived from different
sources were also investigated to provide insight into any potential
difference in their paracrine effects after transplantation [17]. The
cytokine profiles were quantified from the conditioned medium
derived from hiPSC-1-EC, hiPSC-2-EC, hESC-EC, BM-EC and
HUVEC using multiplex ELISA. During normoxic culture,
similar pattern of cytokine expression (ICAM, VEGF, bFGF and
leptin) were observed in the conditioned medium of hiPSC-1-EC,
hiPSC-2-EC and hESC-EC, except that higher levels of HGF and
PIGF were detected in hiPSC-1-EC and hiPSC-2-EC (Figure 3A).
The conditioned medium of BM-EC had significantly higher levels
of VEGF and VCAM and lower levels of ICAM1 than hESC-EC
(all P,0.05, Figure 3A). Furthermore, the conditioned medium of
BM-EC had significantly higher levels of VCAM and lower levels
Table 1. Clinical characteristic of the patients’ marrow MNC used in this study.
Flow cytometry analysis
Patients
Number Sex Age CAD CHF HT DM PCI CABG
Creatinine
(umol/L) %CD34+ %CD3+ %CD11b+ %CD117
1 Male 61 + + - - + - 106 1.26 37.34 21.34 2.92
2 Male 67 + + + + + - 147 1.87 16.9 18.68 1.93
3 Male 70 + + + + + + 104 1.32 15.66 14.41 1.29
4 Male 64 + + + + + 2 146 0.92 34.25 21 0.77
5 Male 60 + + + + + 2 162 1.49 20.81 21.67 2.01
6 Male 61 + + + 2 2 2 104 1.3 49.34 49.21 1.88
CAD= coronary arteries diseases; CHF= chronic heart failure; HT =hypertension; DM=diabetes mellitus; Lipid = hyperlipidemia; PCI = percutaneous coronary
intervention; CABG= coronary artery bypass graft, ‘+’ = present, ‘2’ = absent.
doi:10.1371/journal.pone.0057876.t001
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of SDF1 than hiPSC-1-EC and hiPSC-2-EC (all P,0.05,
Figure 3A). The conditioned medium of the HUVEC had
significantly lower levels of leptin and SDF-1 (Figure 3A).
To mimic the micro-environment in the ischemic tissue, hiPSC-
1-EC and hiPSC-2-EC, hESC-EC, BM-EC and HUVEC were
subjected to hypoxic stress. Multiplex ELISA revealed that the
expression of major angiogenic factors including EGF, HGF,
VEGF, PIGF and SDF-1 were significantly up-regulated in
hiPSC-1-EC, hiPSC-2-EC, hESC-EC, BM-EC and HUVEC
under hypoxia as compared with normoxia (all P,0.05,
Figure 3A and B). Multivariate radar chart analysis showed that
the magnitude of cytokine up-regulation upon hypoxic induction is
more dramatic in hiPSC-1-EC and hiPSC-2-EC and hESC-EC
compared with BM-EC (Figure 3B).
Functional Improvement of Blood Flow in Ischemic Hind-
limbs after Transplantation
The therapeutics efficacy of hiPSC-1-EC, hiPSC-2-EC, hESC-
EC, BM-EC and HUVEC for therapeutic angiogenesis was
compared in a mouse model of hind-limb ischemia. After the
femoral artery ligation, the blood flow of the ischemic limb
decreased to only 3.760.4% of that the non-ischemic control
limbs, confirming the successful induction of acute hind-limb
ischemia. From Day 7 onward, there was significant and
progressive improvement of ischemic limb blood flow in all
groups of mice receiving EC transplantation as compared with
medium group (Figure 4A, all P,0.05). At Day 28, mice treated
with hiPSC-1-EC (44.866.9%), hiPSC-2-EC (38.2%62.6%),
hESC-EC (37.462.5%), BM-EC (39.265.8%) and HUVEC
(29.6%64.9%) transplantation had significantly higher hind-limb
blood flow than the medium group (14.466.2%, all
P,0.05)(Figure 4A). Nonetheless, there were no significant
differences in the blood flow of ischemic limb between those mice
treated with hiPSC-1-EC, hiPSC-2-EC, hESC-EC and BM-EC
throughout the study period (all p,0.05), and their rate of blood
flow improvement were superior to the HUVEC group from Day
0 to 14 (Figure 4A).
Immunohistological staining for vWF in the ischemic limbs at
Day 28 demonstrated increased in capillary density after hiPSC-1-
EC, hiPSC-2-EC, hESC-EC and BM-EC transplantation as
compared with HUVEC group and control media injection
(Figure 4B, all P,0.05). On the other hand, immunostaining for a-
smooth muscle actin failed to reveal any difference in the numbers
of arteries among different groups (Figure 4B, P,0.05), suggesting
the development of angiogenesis rather than arteriogenesis after
EC transplantation.
Histological examination did not reveal any teratoma formation
at the transplanted sites in any of the mice after EC trans-
plantation. Cell retention of transplanted EC was also examined at
Day 7 and Day 28 in a subgroup of animals by immunohistolo-
gical staining for HNA in the ischemic limbs. Comparing the
number of HNA positive cells at Day 7 after transplantation,
minimal transplanted cell retention was observed in all three
groups of mice after EC transplantation as indicated by the
markedly reduced number of HNA positive staining in ischemic
limb harvested on Day 28 (Figure 5A).
To further evaluate the cell retention level and the proliferative
ability of hiPSC-EC, in- vivo live cells imaging was employed to
detect and quantify the emitted bioluminescence from luciferase-
labeled hESC-EC and hiPSC-EC progeny. According to bio-
luminescence emitted from labeled progeny, hESC-EC and
hiPSC-EC could be detected at Day 7 after transplantation and
then started to decline. Nevertheless, transplanted hESC-EC and
hiPSC-EC were still detected at Day 28 after transplantation with
a gradual drop in signal intensity (Figure 5B).
Discussion
Currently, BM-derived stem cells are the most common cell
type investigated in clinical trials for treatment of cardiovascular
diseases [3,4,18]. However, in order to overcome the scarcity and
functional impairment of autologus BM stem cells, EC derived
from pluripotent stem cells, such as hESC have been proposed as
an alternative and unlimited source of cells for therapy. The latest
advances in the generation of hiPSC [10] has shed light into the
field of cell-based therapy by providing an alternative unlimited
source for autologous transplantation which can potentially solve
the problem of availability [19]. In the current study, we sought to
evaluate the therapeutic efficacy of EC derived from different cell
sources in treatment of ischemic cardiovascular diseases.
Here, we confirmed that one hESC line and two hiPSC lines
could be differentiated into functional EC which express
a comparable level of endothelial markers as BM-EC and
HUVEC. In-vitro tube formation and cellular migration assays
revealed that hESC-EC and hiPSC-EC have similar angiogenic
function as BM-EC and HUVEC. Although there was some
discrepancy in the angiogenic cytokine profile in the conditional
medium between hiPSC-EC, hESC-EC, BM-EC and HUVEC at
baseline, significant increased in the level of multiple major
angiogenic cytokines, including EGF, HGF, VEGF, PIGF and
SDF-1 were observed in the conditioned medium derived from all
type of EC after hypoxia. Moreover, hiPSC-EC and hESC-EC
had even greater response to hypoxic induction in their expression
of angiogenic cytokines than the BM-EC and HUVEC. These
angiogenic cytokines have been shown to enhance neovasculariza-
tion in the ischemic sites [20].
Therefore, the increased expression of these angiogenic factors
from the transplanted EC upon hypoxia in the ischemic condition
of the hind-limb could provide paracrine effect to enhance
neovascularization.
In concordance with these observations, our results also
demonstrated a similar overall therapeutic efficacy of EC derived
from hiPSC, hESC and BM-MNC as determined by laser Doppler
blood flow up to Day 28 in the mouse model of hind-limb
ischemia. Despite progressive improvement of blood flow over the
ischemic limbs was observed in serial laser Doppler blood flow
measurement, immunohistochemical staining and luciferase assay
revealed only very small number of the EC remained and
engrafted into the vasculature at the transplanted ischemic limbs.
Therefore, majority of the beneficial effects exert by the
Figure 1. Characterization of derived endothelial-like cells (EC). (A) Phase contrast photos (left panel) showing the morphology of hESC-EC,
hiPSC-EC, bone marrow derived EC (BM-EC) and human umbilical cord endothelial cell (HUVEC) in a confluent culture. Immunofluorescence staining
showed the expression of typical endothelial cells markers including Ulex europaeus lectin (green) and uptake of Di-Acetyl-LDL (red) (second panel) in
hESC-EC, hiPSC-1-EC, BM-EC and HUVEC. Furthermore, expression of CD31, von Willebrand factor (vWF) and intercellular adhesion molecule 1 (ICAM)
were also detected in hESC-EC, hiPSC-EC, BM-EC and HUVEC (B) Flow cytometry analysis revealed the expression of CD31, vWF, Kinase insert domain
receptor (KDR) in hESC-EC, hiPSC-EC, BM-EC and HUVEC (left panel). There were no differences in the percentage of cells with expression of CD31,
vWF, KDR and co-expression of CD31 and KDR between hESC-EC, hiPSC-EC and BM-EC (right panel).
doi:10.1371/journal.pone.0057876.g001
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Figure 2. In- vitro functional assessment of derived endothelial-like cells. (A) Tube formation assay was performed with 16104 cells seeded
onto Matrigel and the presence of micro vessel formation was visualized by phase contrast microscope (1006) after 6 hours of incubation at 37uC.
There was no significant difference in length of tube-like vessels formed by hESC-EC, hiPSC-EC, BM-EC and HUVEC (p.0.05). (B) Modified Boyden
chamber assay was used to determine the migration ability of the hESC-EC, hiPSC-EC, BM-EC and HUVEC. These cells were placed in the inner
chamber and allowed to migrate across the porous membrane toward the outer chamber with the presence of medium alone (control) or medium
supplemented with vascular endothelial growth factor (VEGF). Then, the numbers of migrated cells per mm2 present in the transwell were counted
under light microscope (1006, upper panel). The numbers of migrated cells were significantly increased after supplement with VEGF in hESC-EC,
hiPSC-EC, BM-EC and HUVEC as compared with their corresponding control (*p,0.05). However, there were no differences among those EC in the
number of migrated cells with the presence of medium alone or medium supplemented with VEGF (p,0.05, lower panel).
doi:10.1371/journal.pone.0057876.g002
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Figure 3. Angiogenic cytokine profiles of conditioned medium obtained from derived endothelial-like cells under normoxic and
hypoxic condition. A total of 16105 cells were plated into 6-well gelatin coated plate for overnight incubation, then the cells were washed and
Endothelial Cells Derived from Human Stem Cells
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transplanted EC is likely to be mediated via other mechanisms,
such as paracrine secretion rather than de-novo formation of
vasculature by the transplanted EC [1,21,22]. Furthermore, we
only observed increased angiogenesis rather than arteriogenesis
after EC transplantation.
Our results also confirmed previous findings [23] and showed
that HUVEC cells have a lower capacity in improving blood flow
and neovascularization in the hind-limb ischemic mouse model
than those EC derived from BM, hESC or hiPSC. This finding
suggests that the paracrine function of HUVEC is less effective
than EC derived from other cell sources for enhancing
neovascularization.
Since the initial description of successful generation of hiPSC
from adult fibroblast, several clinical compliance protocols had
been developed, such as the use of xeno-free and feeder-free
system [14] and the generation of hiPSC from donor cells that
does not require an invasive procedure, e.g. urine cells [24] and
hair follicles [25]. Moreover, recent breakthrough of generating
hiPSC using mRNA transfer [26] without the need of viral
mediated transfer has brought the hiPSC technology closer to the
clinic.
To our knowledge, this study is the first to compare the in vitro
and in vivo therapeutic efficacy of EC derived from hiPSC, hESC,
BM and normal human endothelial cells. Although hiPSC-EC
only provide a similar therapeutic efficacy as BM-EC and hESC-
EC, the use of patients-specific hiPSC-EC can circumvent issues
related to the clinical use of hESCs, as well as the need for an
invasive procedure for harvesting an adequate amount of BM cells
cultivated in EBM2 basal medium without supplement for 5 days under normoxic (20% O2) or hypoxic (0.1% O2). Cytokine profiling of their
conditioned mediums obtained were determined by Procarta multiplex bead-based immunoassay kit. (A) Bar charts and (B) multivariate radar chart
showed the expression of epidermal growth factor (EGF), basic fibroblast growth factor (FGF-B), hepatocyte growth factor (HGF), leptin, vascular
endothelial growth factor (VEGF), placental growth factor (PIGF) and stromal derived factor-1 (SDF-1); adhesion molecules including, ICAM1 and
vascular cell adhesion molecule (VCAM) in the conditioned medium upon normoxic and hypoxic treatment.
doi:10.1371/journal.pone.0057876.g003
Figure 4. Improvement of blood perfusion in ischemic hind-limbs after transplantation of derived endothelial-like cells. (A) Laser
Doppler scanning was preformed immediately after ligation of femoral artery to confirm the induction of hind-limb ischemia. Then repeated Doppler
scanning was performed at Day 7, 14, 21 and 28 after transplantation of 3 million hESC-EC, two different hiPSC-ECs, BM-EC, HUVEC or medium alone
into the ischemic muscle. Representative photos from the laser Doppler scanning at Day 0, Day 14 and Day 28 were shown. Blue color represents
lower perfusion and red color represents higher perfusion (upper panel). In each animal, limb perfusion was quantified and the average of the
perfusion ratio against the control limb was calculated in different time point (lower panel). As compared with medium injection, there was
progressive and significant improvement of blood flow over the ischemic limbs after hESC-EC, hiPSC-ECs, BM-EC and HUVEC transplantation (n = 6 in
each group, *p,0.05 vs. medium control at different time points). However, there were no significant differences in the blood flow over the ischemic
limbs among those mice after hESC-EC, hiPSC-EC and BM-EC transplantation (p.0.05 at different time points). (B) Representative photos show the
immunohistochemical staining for von Willebrand factor (vWF) and smooth muscle actin (SMA) of histological sections over the ischemic limbs at Day
28 after hESC-EC, hiPSC-EC, BM-EC or medium injection (upper panel). The number of vessels with positive staining (brown color) for vWF and SMA
were determined under a light microscope with 6400 magnification with 20 random fields. As compared with medium injection, there were
significant higher number of vessels with vWF positive but not SMA over the ischemic limbs after hESC-EC, hiPSC-ECs and BM-EC transplantation (*p
vs. medium control and * vs HUVEC, p,0.05). However, there were no significant differences in the number of vessels with vWF and SMA positive
over the ischemic limbs among those mice after hESC-EC, hiPSC-EC and BM-EC transplantation (p.0.05).
doi:10.1371/journal.pone.0057876.g004
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for transplantation. In this study, ECs with similar functional
characteristics and therapeutic potential could be derived from
two different hiPSC lines. Importantly, we did not observe any
teratoma formation in mice after transplantation of both hESC-
EC or hiPSC-EC, suggesting that the risk of uncontrolled
proliferation or growth from those EC derived from pluripotent
stem cells is low. Nevertheless, this finding needs to be further
confirmed by future studies.
In this study, only 1 out of 6 specimens of BM mononuclear cells
from patients with severe coronary artery disease could be able to
differentiate into functional EC for transplantation due to their
poor survival and proliferation capability as shown in previous
studies [8]. Furthermore, the underlying concomitant conditions
of these patients, such as heart failure, hypertension and diabetes
[5–7] may also offset the function of their BM stem cells. The
observation also highlight that autologous BM-EC transplantation
might be feasible and effective in a small number of patients with
cardiovascular diseases. The low successful rates to obtain
functional EC from BM cells as well as their larger variability in
characteristics are major limitations for their clinical use. Our
results from EC derived from two hiPSCs and one hESC
consistently demonstrated that they are not inferior to BM-EC
for both in-vivo and in-vitro neovascularization. Importantly,
functional EC could be derived from existing hESC and hiPSC
lines despite multiple passages. Thus, these cell types are more
stable sources of functional EC for potential therapeutic applica-
tions.
Taken together, our results showed that functional EC could be
generated from hESC and iPSC with similar therapeutic efficacy
for attenuation of severe hind-limb ischemia. Differentiation of
functional BM-EC was more difficult to achieve in patients with
cardiovascular diseases, and hESC-EC or iPSC-EC are readily
available as ‘‘off-the-shelf’’ format for treatment of tissue ischemia.
This study has limitations. First, the precise mechanism of
therapeutic benefit for each of the cell types remains unknown. In
this study, we showed that only very small numbers of transplanted
cells were detected at Day 28. This finding suggests that paracrine
actions of the transplanted ECs are the likely mechanisms that
Figure 5. Retention of derived endothelial-like cells at Day 7, 14 and 28 after transplantation. (A) Representative photos show the
immunohistochemical staining for human nuclear antigen (HNA) over the ischemic hind-limb at Day 7 and 28 after hESC-EC, hiPSC-1-EC, BM-EC or
medium injection (upper panel). Red arrow indicated engrafted hESC-EC, hiPSC-EC, BM-EC in the ischemic limb with HNA positive (brown), indicating
those cells were from human origin. At Day 7, clusters of HNA positive cells were observed at the injection sites after hESC-EC, hiPSC-1-EC, and BM-EC
transplantation but not after medium injection. At Day 28, only a few HNA positive cells were found around the vasculature at the injection sites after
hESC-EC, hiPSC-1-EC, and BM-EC transplantation. As compared with Day 28, the numbers of HNA positive cells detected at the injection sites were
significantly higher at Day 7 after hESC-EC, hiPSC-1-EC, BM-EC transplantation (*p,0.05, lower panel). (B) Representative photos showing live cells
tracking by quantifying luciferase activity using the Xenogen’s in vivo optical imaging systems at Day 7, 14 and 28 after hESC-EC, hiPSC-1-EC, or
medium injection (upper panel). Luciferase activity was plot as total flux measurement in photons/second/cm2. Declined in intensity of luciferase
activity over time after hESC-EC and hiPSC-1-EC transplantation was shown, suggesting progressive cell loss (n = 4 in each group, lower panel).
doi:10.1371/journal.pone.0057876.g005
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contribute to increased angiogenesis. On the other hand, whether
those transplanted ECs directly contribute to the paracrine effects
is unknown, as other mechanisms such as recruitment of
endogenous local or circulating progenitor cells into the ischemic
tissues are not investigated in this study. Second, the precise role of
different cytokines secreted by the transplanted cells remains
unclear and only limited panel of cytokines were tested in this
study.
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